INF39
25mg
| ≥99%
CSNpharm
INF39 is an irreversible NLRP3 inhibitor with IC50 value of ~100 μM for inhibiton of NLRP3 ATPase, which can inhibit IL-1β release, caspase activation and pyroptosis in THP-1 cells.
More Information
Supplier Page
INF39
2mg
| ≥99%
CSNpharm
INF39 is an irreversible NLRP3 inhibitor with IC50 value of ~100 μM for inhibiton of NLRP3 ATPase, which can inhibit IL-1β release, caspase activation and pyroptosis in THP-1 cells.
More Information
Supplier Page
INF39
50mg
| ≥99%
CSNpharm
INF39 is an irreversible NLRP3 inhibitor with IC50 value of ~100 μM for inhibiton of NLRP3 ATPase, which can inhibit IL-1β release, caspase activation and pyroptosis in THP-1 cells.
More Information
Supplier Page
INF39
5mg
| ≥99%
CSNpharm
INF39 is an irreversible NLRP3 inhibitor with IC50 value of ~100 μM for inhibiton of NLRP3 ATPase, which can inhibit IL-1β release, caspase activation and pyroptosis in THP-1 cells.
More Information
Supplier Page
INF39
10mg
| ≥99%
CSNpharm
INF39 is an irreversible NLRP3 inhibitor with IC50 value of ~100 μM for inhibiton of NLRP3 ATPase, which can inhibit IL-1β release, caspase activation and pyroptosis in THP-1 cells.
More Information
Supplier Page
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
INO-1001 is a potent inhibitor of PARP with IC50 of < 50 nM in CHO cells and a mediator of oxidant-induced myocyte dysfunction during reperfusion.
More Information
Supplier Page
CSNpharm
INO-1001 is a potent inhibitor of PARP with IC50 of < 50 nM in CHO cells and a mediator of oxidant-induced myocyte dysfunction during reperfusion.
More Information
Supplier Page
CSNpharm
CSNpharm
CSNpharm
Disodium 5′-inosinate, obtained from bacterial fermentation of sugars, is as a food additive and often found in a variety of other snacks.
More Information
Supplier Page
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
IOX1
10mg
| ≥99%
CSNpharm
IOX1 is the broad-spectrum inhibitor of 2OG oxygenases and its IC50 for KDM4A/KDM3A and KDM4C/KDM6B/KDM2A/KDM4E are 0.6/0.1 μM and 0.6 μM/1.6 μM/1.8 μM/2.3 μM.
More Information
Supplier Page
IOX1
1mg
| ≥99%
CSNpharm
IOX1 is the broad-spectrum inhibitor of 2OG oxygenases and its IC50 for KDM4A/KDM3A and KDM4C/KDM6B/KDM2A/KDM4E are 0.6/0.1 μM and 0.6 μM/1.6 μM/1.8 μM/2.3 μM.
More Information
Supplier Page
IOX1
5mg
| ≥99%
CSNpharm
IOX1 is the broad-spectrum inhibitor of 2OG oxygenases and its IC50 for KDM4A/KDM3A and KDM4C/KDM6B/KDM2A/KDM4E are 0.6/0.1 μM and 0.6 μM/1.6 μM/1.8 μM/2.3 μM.
More Information
Supplier Page
IOX1
50mg
| ≥99%
CSNpharm
IOX1 is the broad-spectrum inhibitor of 2OG oxygenases and its IC50 for KDM4A/KDM3A and KDM4C/KDM6B/KDM2A/KDM4E are 0.6/0.1 μM and 0.6 μM/1.6 μM/1.8 μM/2.3 μM.
More Information
Supplier Page
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
IPA-3
50mg
| ≥98%
CSNpharm
IPA-3 is a selective non-ATP competitive PAK1 inhibitor with IC50 of 2.5 μM, no inhibition to group II PAKs (PAKs 4-6).
More Information
Supplier Page
IPA-3
5mg
| ≥98%
CSNpharm
IPA-3 is a selective non-ATP competitive PAK1 inhibitor with IC50 of 2.5 μM, no inhibition to group II PAKs (PAKs 4-6).
More Information
Supplier Page
IPA-3
10mg
| ≥98%
CSNpharm
IPA-3 is a selective non-ATP competitive PAK1 inhibitor with IC50 of 2.5 μM, no inhibition to group II PAKs (PAKs 4-6).
More Information
Supplier Page
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
Ipratropium bromide is a synthetic derivative of the alkaloid atropine anticholinergic properties with anticholinergic properties.
More Information
Supplier Page
CSNpharm
Ipratropium bromide is a synthetic derivative of the alkaloid atropine anticholinergic properties with anticholinergic properties.
More Information
Supplier Page